Within a prospective study we analyzed hematopoietic chimerism in serial peripheral blood samples taken from 55 patients with acute leukemias (ALL 21, AML 20, MDS 14) with a median age of 13.5 years at very short time intervals following allogeneic bone marrow transplantation (allo-BMT). The investigation was performed to determine the implications of mixed hematopoietic chimerism (MC) with regard to the clinical outcome in patients with acute leukemias after allo-BMT. Analysis of chimerism was performed by PCR of variable number of tandem repeat (VNTR) sequences with a maximum sensitivity of 0.8%. Thirteen male patients transplanted with the marrow of a female donor were also studied by amplification of a Y-chromosomespecific alphoid repeat (0.1-0.01% sensitivity). VNTR analysis in 55 patients revealed complete chimerism (CC) in 36 cases, MC in 18 follow-ups and autologous recovery in one patient. Quantitative analysis of MC identified 10/18 patients with increasing autologous patterns in whom 9/10 subsequently relapsed. The patient with autologous recovery relapsed as well. Eight of 18 patients with MC showed decreasing amounts of autologous DNA and became CC upon further follow-up. In contrast, only 7/36 patients with CC in the prior analysis of chimerism status relapsed. However, in 4/7 patients the interval between last CC confirmation and relapse was more than 4 months. In 2/7 patients autologous DNA was not detectable in peripheral blood but in bone marrow aspirates. One of these seven patients developed a fulminant relapse within 3 weeks. The probability of relapse-free survival for patients with CC is 0.67 (n = 36), for patients with decreasing MC 1.0 (n = 8) and for patients with increasing MC 0.1 (n = 10). In summary, the results demonstrate that serial and quantitative chimerism analysis at short time intervals by PCR provides a reliable and rapid screening method for the early detection of recurrence of underlying dis- ease and is therefore a prognostic tool to identify patients at highest risk of relapse.
Over the past decades, allogeneic bone marrow transplantation (allo-BMT) has become the treatment of choice for selected patients with acute leukemias and for patients with myelodysplastic syndromes (MDS). 1, 2 The success of this treatment modality in this group of patients is mainly affected by recurrence of the underlying disease. 3 Factors responsible for relapse may be insufficient conditioning regimens or a deficient graft-versus-leukemia (GVL) effect eventually due to decreasing amounts of effector cells or to their functional ineffectiveness. Following allo-BMT, complete donor-derived hematopoiesis has been considered essential for sustained engraftment and for the prevention of relapse. Various techniques such as cytogenetic analysis, [4] [5] [6] erythrocyte phenotyping 7 and restriction fragment length polymorphisms (RFLPs) [8] [9] [10] [11] have been used to document chimerism after allo-BMT. These studies have left the question unanswered whether patients with mixed hematopoietic chimerism (MC) do have an increased risk of relapse. [12] [13] [14] [15] [16] Some investigators found no correlation between MC and relapse in patients with acute leukemias, 7, 16, 17 while others described patients with high levels of residual and/or rapidly increasing amounts of recipient cells to carry a high risk of developing relapse. 13, [18] [19] [20] The conflicting results found in the literature might be explained on the basis of the biology of acute leukemias whereby relapses generally develop within short time periods. Therefore, studies with relatively long intervals in the follow-up of patients may have missed the critical and transient stage of MC. The introduction of PCR methods suitable for amplification of minisatellite regions offers the potential to study the mechanisms and kinetics (1) of chimerism after allo-BMT, [21] [22] [23] [24] (2) of graft rejection, 5 (3) of recurrence of leukemia [12] [13] [14] and highlights, in part, patients with increased risk of relapse. Most recently, studies using serial investigations of chimerism based on these PCR techniques have led to new insights into the development of MC post transplant. It has been shown that relapse is preceded by a critical and transient stage of MC characterized by increasing amounts of autologous cells. 18 These observations have lately been confirmed by Ramìrez et al 19 in a study of post-transplant chimerism with close follow-up, demonstrating that all patients with relapse showed prior MC with increasing recipient patterns. 19 Recently, we have been able to demonstrate in a prospective study of 32 patients with leukemias using a quantitative PCR-based analysis of post-transplant chimerism with sufficiently short time intervals, that patients with increasing MC do have a significantly enhanced risk of developing relapse (P = 0.0079, n = 6). 20 Here, we present the results of a prospective multicenter trial in a large group of patients (n = 55) with acute leukemias and MDS and demonstrate that the quantitative and serial investigation of post-transplant chimerism offers the possibility of identifying patients at highest risk for relapse to whom additional therapy should be offered in order to prevent frank hematological relapse.
Materials and methods

Patients
The study included 55 prospectively investigated patients with acute leukemias and MDS following allo-BMT. Disease status, age of recipient, conditioning regimen, GVHD prophylaxis and outcome of BMT are shown in Table 1 . All patients were transplanted with unmanipulated bone marrow either from an HLA-identical family donor (40/55), from a partially mismatched family donor (4/55) or from an HLA-identical unrelated donor (11/55). The transplantation procedures were performed at the University of Tübingen, (Dept of Pediatric Hematology/Oncology and the Dept of Hematology/Oncology, University Medical Center) and at the University Children's Hospital Freiburg, Germany, between January 1993 and February 1997. Informed consent of patients and parents when appropriate were obtained according to institutional guidelines. Clinical grading of aGVHD was performed according to Refs 25 and 26.
Specimens
Peripheral blood samples were collected from the donor and recipient before transplant and from the recipient at regular intervals after engraftment. Genomic DNA was isolated from fresh or frozen blood samples as recently described. 27 
PCR analysis
In order to evaluate the possible dynamics of chimerism after allo-BMT we established a quantitative PCR approach for the amplification of VNTR sequences as previously described. 27 Briefly, pretransplant recipient and donor DNA samples were amplified with seven different primer pairs to obtain at least one informative locus. Standardized mixed chimeric samples were generated by mixing pretransplant recipient and donor DNA in a range of percentages for each individual case (Figure 1 ). PCR analysis for the informative locus was carried out on sequential patient samples using the informative primer pair. PCR products were separated by polyacrylamide gel electrophoresis. After staining with ethidium bromide, signals were analyzed densitometrically and results were taken on the basis of individual standard curves ( Figure 1 ). The maximum sensitivity with this competitive PCR approach was 0.8%. Post-transplant DNA samples were investigated in sequence and the signal intensities were compared to the standard curves.
Y-specific amplification was performed as described by Witt and Erickson. 39 Precautions to avoid contamination were as follows: all analyses for the detection of Y-specific sequences were exclusively conducted by female investigators. Amplification was always performed with recipient pretransplant DNA as positive and donor DNA as negative controls and with the previous preceding recipient samples each time a new sample was investigated. The maximum sensitivity with this approach was 0.1-0.01%.
Statistics
Statistical analysis was performed using Fisher's exact test. A P value of Ͻ0.05 was considered significant. Survival data were analyzed using Kaplan-Meier product limit life table statistics and the resulting survival curves were compared using the log rank test.
Evaluation of the patients
Following engraftment peripheral blood samples were investigated weekly as soon as the leukocyte count exceeded 500/l. After discharge, the majority of the patient samples were collected and analyzed monthly within an observation period of 18 months after allo-BMT, with the exception of a very few patients who could not be observed at short time intervals as defined by our study design (see below). The follow-up of patients from January 1994 until March 1997 ranged from 2 to 39 months (median 12.4 months). If an MC was detectable, we intensified the monitoring regimen by analyzing patient samples twice a week during the first 100 days post transplant.
Definition of chimerism
The patients were subdivided into different groups exclusively based on the analysis by VNTR-PCR within the limits of given sensitivity of about 1%. Patients who showed no evidence of autologous cells at any time post transplant were considered to be complete chimeras (CC). Secondly, patients who showed both recipient and donor cells in the peripheral blood were defined as mixed chimeras (MC). Patients who developed increasing amounts of autologous DNA were referred to as increasing mixed chimeras and patients with decreasing autologous cells displayed decreasing mixed chimeras.
Results
Correlation of chimerism status and relapse analyzed by VNTR-PCR
The CC status was detected in 36 out of 55 patients at any given time during the post-transplant monitoring. Eighteen ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; AR = autologous recovery; ATG = antithymocyte globulin; BU = busulfan; CC = complete chimerism; CsA = cyclosporin A, CY = cyclophosphamide; ETO = etoposide; de-MC = decreasing mixed chimerism; in-MC = increasing mixed chimerism; MDS = myelodysplastic syndrome; MEL = melphalan; MTX = methotrexate; THI = thiotepa; TBI = total body irradiation; UPN = unique patient number. out of 55 patients developed MC (33%) during the observation period. One patient showed autologous recovery with subsequent relapse ( developed a fulminant relapse and even an investigation interval of 4 weeks was too long to detect the critical transient stage of MC in this particular patient. Patients with MC (n = 18) generally developed certain dynamics and could be classified into two groups according to patients with increasing MC (n = 10) and into patients with decreasing MC (n = 8). All patients with decreasing MC turned into CC during the post-transplant follow-up and remained in complete remission. Nine of the 10 patients with increasing MC subsequently relapsed. Only one patient with AML (UPN 24) who showed slowly increasing recipient cells fully rejected the graft on day +190 post transplant without recurrence of underlying disease (Figure 2) . In summary, patients who showed MC during follow-up have a significantly enhanced risk of developing relapse (P = 0.029; n = 18) compared to patients with CC. Analysis of the dynamics of post-transplant chimerism allowed identification of the subgroup of patients with increasing MC who were at highest risk for relapse (P Ͻ 0.0001; n = 10) with an odds ratio of 37 (95% confidence interval: 5-749). The evolution of relapse in patients with acute leukemias was often relatively rapid and therefore close post-transplant monitoring was needed to recognize the recurrence of autologous hematopoiesis before frank hematological relapse occurred.
Prognostic significance of mixed chimerism with respect to leukemic relapse and survival
The prognostic significance of residual or reappearing recipient hematopoiesis on the duration of leukemia-free survival (LFS) and overall survival was determined by Kaplan-Meier analysis and is plotted in Figure 3 . Significant differences were found between patients with CC (n = 36) and increasing MC (n = 10) with respect to the duration of LFS (P Ͻ 0.0001) and to overall survival (P = 0.0012). The 2-year probabilities of LFS and for survival for children with CC were 68 and 64%, respectively. The 2-year probabilities for patients with increasing MC regarding LFS and overall survival were 10%. For patients with decreasing MC the probabilities for LFS and overall survival were 100 and 72%, respectively. A theoretical problem of this analysis might be that the groups are defined by a factor not known at the start of the study. Since some patients with MC must survive for a certain period in order to develop MC the survival analysis may have diminished the real differences between MC and CC, which would be even greater than the observed ones.
Correlation of chimerism status and relapse by Y-chromosome-specific markers
Thirteen male patients were transplanted with the marrow of a female donor and therefore Y-sequence specific PCR analysis was performed in addition to analysis of VNTR. The sensitivity of detecting a minor cell population with this PCR approach is about 0.1-0.01% and therefore much more sensitive than a competitive VNTR-PCR approach. The 2-year probabilities of LFS and OS for patients with CC were 68 and 64%, respectively. The 2-year probabilities for patients with in-MC for LFS and OS were 10%.
The incidence of MC in this subgroup of patients was 12/13 (92%) with Y-specific PCR as compared to 7/12 (58%) with VNTR-PCR. In comparison to the incidence of MC in the total group of patients (18/55 = 33%) with VNTR-PCR a bias towards MC was found in this subgroup. Four out of these 13 patients developed relapse and in all of these four patients increasing MC could be detected by means of VNTR-PCR. The other nine patients remained in continuous remission and MC (as determined by Y-specific PCR) became CC in all patients. No additional information could be obtained in our series with the more sensitive method regarding the potential to recognize the beginning of relapse. It is of interest that no stable MC or MC at the level below 1% could be detected in our series.
Correlation of graft-versus-host disease (GVHD) and chimerism status
GVHD grades II-IV was only seen in four of 18 patients with MC (22.2%), but in 16/36 patients with CC (44.4%). However, the difference between MC status and GVHD grading of less than grade II did not reach statistical significance (P = 0.103). The state of chimerism and GVHD grading are given in Table 3 .
Discussion
The impact of MC for the prediction of relapse after allo-BMT has been investigated by several groups over the last decade. [28] [29] [30] [31] These studies have left unanswered the question of whether patients with acute leukemias and with MC post transplant do have an increased risk of relapse. 15, 19, 32 The conflicting results in the literature might in part be explained on the basis of the underlying disease whereby relapses from acute leukemias generally develop within short time periods. Studies with relatively long intervals in patient follow-up may therefore have missed the critical and transient stage of MC. The introduction of highly sensitive methods for the identification of post-transplant engraftment and chimerism, such as in situ hybridization (FISH) or PCR technique, allowed the detection of MC status more frequently than previous analyses with cytogenetics or restriction fragment length polymorphism (RFLP). 21, 24, [33] [34] [35] Most recently, studies using serial analyses of post-transplant chimerism have highlighted patients with rapidly increasing amounts of autologous hematopoiesis to be at highest risk for relapse. [18] [19] [20] Moreover, these studies with relatively short investigation intervals could show that in patients with acute leukemias frank hematological relapse was preceded by reappearance of recipient Table 3 Correlation between state of chimerism and GVHD 18, 19 In our recently published study, where we investigated post-transplant chimerism with a quantitative PCR approach at very short time intervals, we could demonstrate a significant correlation between patients with increasing MC and relapse. 20 In the present study, we have updated our results and included the data of our analysis from patients with acute leukemias transplanted in two additional centers. Results presented in this study from patients from three centers confirmed the results of the previous study from a single center. It was demonstrated that patients with increasing amounts of autologous patterns (n = 10) carried a significantly enhanced risk of developing relapse (P Ͻ 0.0001; odds ratio 37). On the contrary, patients who showed MC following engraftment and developed decreasing autologous signals (n = 8), converted to CC and remained in continuous remission.
GVHD GVHD grade 0-I grade II-IV
In our previous pilot study we found that 3/32 patients with CC in the prior analysis of chimerism had relapsed. 20 In all three patients, it had not been possible to perform screening of chimerism at short intervals. Due to this gap in the observation period, we hypothesized that the critical stage of MC before hematological relapse may have been missed. 20 Interestingly, in two additional patients in this multi-center study it was not possible to detect MC in the peripheral blood at the time relapse was diagnosed in the bone marrow. PCR analysis of a bone marrow aspirate, however, showed a 40% autologous population. Therefore, serial chimerism analysis of the peripheral blood may not highlight all patients at risk of relapse even if performed at very short intervals.
Thirteen male patients grafted with a female donor could be analyzed, in addition to the investigation with VNTR markers, by a highly sensitive PCR approach for the detection of Y-chromosome. Ninety-two percent of the patients investigated in this way showed a certain degree of MC. Only four patients relapsed and all showed increasing autologous DNA which could be detected by VNTR-PCR before hematological relapse was diagnosed. The others remained in remission. Taken together, the detection of MC lower than 1% autologous cells has no predictive value regarding relapse. This confirms previous reports of Landman-Parker 36 and Petit.
30
In our series of 55 patients with acute leukemias we found a highly significant correlation between patients with increasing MC and relapse (P Ͻ 0.0001). Molloy et al 18 who performed similar investigations in patients with ALL transplanted with T cell-depleted marrow from unrelated donors showed that patients with increasing MC carried a high risk of relapse. In contrast to our findings they could not find a significant correlation between patients with increasing MC and relapse. These discordant results may in part be explained by the hypothesis of Roux et al 15 suggesting that the clinical impact of MC depends on a variety of influences such as the underlying disease and the influence of any GVL effect in mediating remission. Based on the results for UD BMT in children when the LFS is similar with or without T cell depletion of the marrow 18, 37 it has been assumed that the GVL effect plays a minor role in ALL patients. But a weak GVL effect caused by T cell depletion may be responsible for a higher incidence of MC in these patients. Another explanation for the discordant findings might be patient selection. Nine out of 10 patients with increasing MC in our series were patients with AML or MDS (Table 2) . Only one patient with ALL showed increasing MC. Thus the majority of patients with increasing MC in our group had myeloid malignancies and were transplanted with unmanipulated marrow whereas all patients in the study of Molloy et al had ALL and were transplanted with T cell-depleted marrow.
However, Ramìrez et al 19 published their investigations on a small group of 15 pediatric patients with ALL who were transplanted with unmanipulated marrow. They could demonstrate that all patients who relapsed (6/15) showed increasing amounts of recipient cells before hematological relapse was diagnosed. These data support our finding that the serial and quantitative analysis of hematopoietc chimerism at short time intervals in patients with acute leukemias transplanted with unmanipulated marrow offers the potential to identify patients at the highest risk for relapse. In the survival analysis of our data ( Figure 3 ) it is of note that treatment failure was mainly caused by relapse. Based on these results we have recently started to treat patients with rapidly increasing recipient cells by a stepwise strategy of withdrawal of post-transplant immunosuppression and/or by application of donor lymphocyte infusion.
The benefit of immunomodulation strategies for patients with acute leukemias 38 who are judged to be at high risk of relapse on the basis of increasing MC will be the subject of future studies. Data presented in this report provide a rational basis for the development of novel strategies aimed at reducing the rate of relapse from acute leukemia following allo-BMT.
